BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wesseling M, de Poel JHC, de Jager SCA. Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player. ESC Heart Fail 2020;7:1488-501. [PMID: 32424982 DOI: 10.1002/ehf2.12728] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Sabbatinelli J, Giuliani A, Bonfigli AR, Ramini D, Matacchione G, Campolucci C, Ceka A, Tortato E, Rippo MR, Procopio AD, Moretti M, Olivieri F. Prognostic value of soluble ST2, high-sensitivity cardiac troponin, and NT-proBNP in type 2 diabetes: a 15-year retrospective study. Cardiovasc Diabetol 2022;21. [DOI: 10.1186/s12933-022-01616-3] [Reference Citation Analysis]
2 Leancă SA, Crișu D, Petriș AO, Afrăsânie I, Genes A, Costache AD, Tesloianu DN, Costache II. Left Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment. Life (Basel) 2022;12:1111. [PMID: 35892913 DOI: 10.3390/life12081111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Chen M, Ding N, Mok Y, Mathews L, Hoogeveen RC, Ballantyne CM, Chen LY, Coresh J, Matsushita K. Growth Differentiation Factor 15 and the Subsequent Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. Clin Chem 2022:hvac096. [PMID: 35762561 DOI: 10.1093/clinchem/hvac096] [Reference Citation Analysis]
4 Boxhammer E, Schmidbauer L, Mirna M, Paar V, Hammerer M, Hoppe UC, Lichtenauer M. How Do Cardiovascular Biomarkers Behave in Patients with Severe Aortic Valve Stenosis with and without Echocardiographically Proven Pulmonary Hypertension?—A Retrospective Study of Biomarker Trends before and after Transcatheter Aortic Valve Replacement. Applied Sciences 2022;12:5765. [DOI: 10.3390/app12125765] [Reference Citation Analysis]
5 Karakuş-Epçaçan Z, Ramoğlu MG, Epçaçan S. Increased serum concentrations of growth differentiation factor-15 in children with acute rheumatic fever. Cardiol Young 2022;:1-6. [PMID: 35585689 DOI: 10.1017/S1047951122001640] [Reference Citation Analysis]
6 Evans BR, Yerly A, van der Vorst EPC, Baumgartner I, Bernhard SM, Schindewolf M, Döring Y. Inflammatory Mediators in Atherosclerotic Vascular Remodeling. Front Cardiovasc Med 2022;9:868934. [DOI: 10.3389/fcvm.2022.868934] [Reference Citation Analysis]
7 Abboud A, Nguonly A, Bean A, Brown KJ, Chen RF, Dudzinski D, Fiseha N, Joice M, Kimaiyo D, Martin M, Taylor C, Wei K, Welch M, Zlotoff DA, Januzzi JL, Gaggin HK. Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study. Open Heart 2021;8:e001704. [PMID: 34663746 DOI: 10.1136/openhrt-2021-001704] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Wu X, Wang Y, Ren Z, Li L, Qian W, Chen Y, Ren W. Association between Growth Differentiation Factor-15 and Risk of Cardiovascular Diseases in Patients with Adult Growth Hormone Deficiency. Int J Endocrinol 2021;2021:5921863. [PMID: 34394348 DOI: 10.1155/2021/5921863] [Reference Citation Analysis]
9 Owens WA, Walaszczyk A, Spyridopoulos I, Dookun E, Richardson GD. Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls. Mech Ageing Dev 2021;198:111540. [PMID: 34237321 DOI: 10.1016/j.mad.2021.111540] [Cited by in F6Publishing: 15] [Reference Citation Analysis]
10 Miranda CP, Botoni FA, Rocha MODC. Serum Levels of BDNF in Cardiovascular Protection and in Response to Exercise. Arq Bras Cardiol 2021;116:510. [PMID: 33909783 DOI: 10.36660/abc.20201001] [Reference Citation Analysis]
11 Hasanpour Segherlou Z, Nouri-Vaskeh M, Noroozi Guilandehi S, Baghbanzadeh A, Zand R, Baradaran B, Zarei M. GDF-15: Diagnostic, prognostic, and therapeutic significance in glioblastoma multiforme. J Cell Physiol 2021;236:5564-81. [PMID: 33580506 DOI: 10.1002/jcp.30289] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Bilchenko A, Vysotska К. INTERRELATIONS BETWEEN GROWTH DIFFERENTIATION FACTOR 15, P-SELECTIN AND GALECTIN-3 AND CLINICAL COURSE IN PATIENTS WITH ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS. EUREKA: Health Sciences 2020;5:3-9. [DOI: 10.21303/2504-5679.2020.001409] [Reference Citation Analysis]
13 Wesseling M, de Poel JHC, de Jager SCA. Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player. ESC Heart Fail 2020;7:1488-501. [PMID: 32424982 DOI: 10.1002/ehf2.12728] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]